AlphaMadera's AlphaVal page computes SOPHiA GENETICS S.A.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag SOPH as undervalued, fairly valued, or overvalued.

What is SOPHiA GENETICS S.A.'s fair value?

Fair value for SOPH is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value SOPH?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from SOPH's most recent reported fundamentals.

SOPH - SOPHiA GENETICS S.A.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $7.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: SOPH has had negative net income and negative EPS in all 5 available fiscal year(s). Quality gate: persistently unprofitable companies are excluded.